The ability to create therapeutic immune cells in the body will significantly lower costs and patient burden by creating a simple drug model. The new challenges created by such a modality include dose control, off target safety concerns and ability to redose. Lupagen has created a delivery device to address these challenges. At the bedside, MNCs are removed for a short time, incubated with the gene delivery vehicle and returned to the patient in a closed loop system. For the subset of cell therapies where only gene delivery is required, extracorporeal delivery is a possible alternative. Lupagen works with biotech and pharmaceutical companies to develop their in vivo programs by supplying systems for preclinical and clinical studies.